医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
11期
146
,共1页
紫杉醇%奈达铂%子宫内膜癌
紫杉醇%奈達鉑%子宮內膜癌
자삼순%내체박%자궁내막암
paclitaxel%nedaplatin%endometrial cancer
目的观察紫杉醇与奈达铂联合化疗治疗晚期子宫内膜癌的疗效和毒副反应.方法32例晚期子宫内膜癌初治患者,17例接受紫杉醇+奈达铂(TP组)方案,同期接受 CAP(环磷酰胺+阿霉素+顺铂)方案(CAP 组)15例进行比较.结论紫杉醇联合奈达铂治疗晚期子宫内膜癌依从性好,毒副反应可以耐受.
目的觀察紫杉醇與奈達鉑聯閤化療治療晚期子宮內膜癌的療效和毒副反應.方法32例晚期子宮內膜癌初治患者,17例接受紫杉醇+奈達鉑(TP組)方案,同期接受 CAP(環燐酰胺+阿黴素+順鉑)方案(CAP 組)15例進行比較.結論紫杉醇聯閤奈達鉑治療晚期子宮內膜癌依從性好,毒副反應可以耐受.
목적관찰자삼순여내체박연합화료치료만기자궁내막암적료효화독부반응.방법32례만기자궁내막암초치환자,17례접수자삼순+내체박(TP조)방안,동기접수 CAP(배린선알+아매소+순박)방안(CAP 조)15례진행비교.결론자삼순연합내체박치료만기자궁내막암의종성호,독부반응가이내수.
Objective To evaluate the results of combined chemotherapy with paclitaxel plus nedaplatin in the treatment of advanced endometrial cancer. Result The TP group response rate was 41.2%, The other group was 40.0%. There was no significant difference between the two groups (P > 0.05). Conclusion Paclitaxel combined with nedaplatin in the treatmentof advanced endometrial cancer has good patient compliance, and the toxicities can be tolerated.
